Cantor Fitzgerald raises Ultragenyx stock price target on gene therapy approval
Cantor Fitzgerald raised its price target for Ultragenyx (RARE) to $39 from $33 after FDA approval of its gene therapy, FAYUVI, for Sanfilippo syndrome type A. The stock trades at $14.50, below the analyst consensus range. Cantor increased its success probability estimate and pricing forecast, including a priority review voucher sale. Despite a 37% YTD decline, InvestingPro suggests the shares are undervalued.
How this was made
The 30-second read
Why it matters
The approval could drive share price higher and attract further investor interest.
Market read
Regulatory clearance for a rare‑disease therapy is a material catalyst for the stock and sector.
What to watch
Potential pricing pressure if reimbursement negotiations are tough.
Background
Analyst Cantor Fitzgerald raised price target to $39 after FDA approval of FAYUVI.
Ticker impact
Ultragenyx received FDA approval for its gene therapy FAYUVI for Sanfilippo syndrome type A.
potential upside as analysts raise targets
Regulatory clearance removes a major hurdle and expands market opportunity.
Market effects
Boosts biotech sector sentiment on gene‑therapy approvals.
Positive for US biotech investors.
Highlights continued pipeline progress in rare‑disease therapeutics.
Counterpoint
Recent Phase 3 failure in Angelman syndrome may temper enthusiasm.
Key entities
- companyUltragenyx Pharmaceutical
Developer of FAYUVI gene therapy.
- analystCantor Fitzgerald
Raised price target and upgraded rating.
